Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of gemtuzumab ozogamicin scheduling and post-remission glasdegib in newly diagnosed AML
2019-003913-32Phase 3Completed
- Sponsor
- Heidelberg University Faculty of Medicine
- Start
- Jul 2020
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glasdegib and gemtuzumab ozogamicin in acute myeloid leukemia (AML) (4 arms), sponsored by Heidelberg University Faculty of Medicine. Primary endpoint: MRD negativity after induction therapy. Started Jul 2020; status: completed.
02
Drugs
glasdegibgemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-003913-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003913-32.